Used primarily in the treatment of certain blood cancers, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It works by inhibiting a specific enzyme called phosphoinositide 3-kinase delta (PI3Kδ), which plays a key role in the survival and spread of malignant B-cells. By blocking this pathway, the drug helps reduce tumor growth and promotes cancer cell death. It is often prescribed for patients who have relapsed or are refractory to other treatments, offering an option for those with limited therapeutic alternatives. The compound has shown efficacy in reducing lymph node size, controlling disease progression, and improving overall survival in clinical settings.